Stromal vascular fraction (SVF) therapy for treatment of various diseases: delivering safety of the first patented svf technique in indonesia

Abstract

Background & Aim To report the safety of SVF therapy done by the first patented processing technique in Indonesia for treating various diseases via various routes of administration. Methods, Results & Conclusion Stromal vascular fraction (SVF) therapy has been performed over the past seven years to treat 493 patients by our group in five clinical centers. SVF was isolated from the lipoaspirate collected from each respective patient through a simple manual liposuction procedure. For each patients, blood was drawn as well to isolate platelet-rich plasma (PRP). SVF and PRP were administered to all subjects by intravenous (IV) injection in an autologous manner, with minority group within the population received an additional spinal, intra-articular, or subcutaneous injections, or combination of several injection sites. The top 5 common diseases were diabetes mellitus, antiaging, degenerative musculoskeletal disease, cardiovascular disease, and autism. On 2016 we patented a new technique called H-Remedy and use it for 402 patients since, 224 males (55.7%) and 178 females (44.3%) aged 1 to 86 year old (median = 55). Lipoaspirate volume was from 10 ml to 415 ml (median = 95) and total number of SVF was ranged between 0.2 × 10^6 per 10 ml to 5.5 × 10^6 per 10 ml (median = 22.4 × 10^6 per 10 ml). The total of 87 patients (21.6%) received 4 times SVF treatments, 161 patients (40%) received 3 times SVF treatments, and 114 patients (28.4%) received 2 times SVF treatments, all during 2 month period. Only 40 patients (10%) received 1 time SVF treatment. It was determined that any complications observed during the treatments with H-Remedy had been identified as a result of spinal or intra-articular injections and not related with direct therapeutic effect from SVF or PRP. These minor side effects had been identified early and successfully treated. In conclusion, the technique and clinical protocol were considered as safe and feasible, and therefore can be used to the next phase of trial to evaluate the efficacy of SVF therapy.